A company focusing on stem-cell therapies is joining the Kansas City Animal Health Corridor.
MediVet Biologics announced it will open a lab in Manhattan in early October. The lab will develop patented technology that the company bought from Kansas State University earlier this year.
MediVet has dual headquarters in central Kentucky and Sydney, Australia. The company specializes in regenerative medicine, including a process for using an animal’s stem cells for pain relief and a vaccine designed to aid in the treatment of cancer in dogs.
The Manhattan lab will be MediVet’s second in the United States. The company plans to locate the lab in the Kansas Entrepreneurial Center in Manhattan initially and is looking at options for a permanent site in the city, according to a release.
In June, MediVet bought a patent involving umbilical cord matrix stem cells. The technology, developed by a team at K-State led by Dr. Mark Weiss, involves harvesting, isolating and culturing stem cells, which then can be turned into other cell types for use in treating mammals. The technology is in pre-clinical development as a potential treatment for musculoskeleton and internal medicine uses.
MediVet CEO Jeremy Delk said in a release that the Manhattan lab would help the company expand in the equine health market and further development of a canine cancer vaccine with K-State Assistant Professor Raelene Wouda.
Kent Glasscock, president of the Kansas State University Institute for Commercialization, also called the news a win for the area economy.
“This success story really speaks to the talent and innovation at Kansas State University,” Glasscock said in a release. “Having a global animal health company spin up a lab in Manhattan underscores its interest in pursuing the type of quality research that we see happening at the university, as well as the infrastructure the city has worked to create that makes Manhattan welcoming to entrepreneurs and new businesses.”